Molecular Biology of Preneoplastic Lesions of the Lung

Lung Cancer, Third Edition

Volumn , Issue , 2008, Pages 84-98

  Wistuba, Ignacio I ^a   Gazdar, Adi F ^b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Lung cancer; Molecular biology; Preneoplastic lesions; Squamous cell carcinoma

Indexed keywords

EID: 79960599272     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470696330.ch5     Document Type: Chapter

References (102)

1. Jemal A, Murray T, Ward E et al. Cancer statistics, 2005. CA Cancer J Clin Jan-Feb 2005; 55(1):10-30.
2. Minna JD, Gazdar A. Focus on lung cancer. Cancer Cell 2002; 1:49-52.
3. Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC. Tumours of the lung. In: Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC (eds). Pathology and Genetics: Tumours of the Lung, Pleura, Thymus and Heart. Lyon: International Agency for Research on Cancer (IARC), 2004:9-124.
4. Colby TV, Wistuba II, Gazdar A. Precursors to pulmonary neoplasia. Adv Anat Pathol 1998; 5(4):205-15.
5. Kerr KM. Pulmonary preinvasive neoplasia. J Clin Pathol 2001; 54:257-71.
6. Franklin W, Wistuba I, Geisinger K et al. Squamous dysplasia and carcinoma in situ. In: Travis W, Brambilla E, Muller-Hermelink HK, Harris CC (eds). Pathology and Genetics Tumors of the Lung, Pleura, Thymus and Heart. Lyon: International Agency for Research on Cancer (IARC), 2004:68-72.
7. Wistuba II, Behrens C, Milchgrub S et al. Sequential molecular abnormalities are involved in the multistage development of squamous cell lung carcinoma. Oncogene 1999; 18:643-50.
8. Wistuba II, Berry J, Behrens C et al. Molecular changes in the bronchial epithelium of patients with small cell lung cancer. Clin Cancer Res 2000; 6:2604-10.
9. Wistuba II, Behrens C, Virmani AK et al. High resolution chromosome 3p allelotyping of human lung cancer and preneoplastic/preinvasive bronchial epithelium reveals multiple, discontinuous sites of 3p allele loss and three regions of frequent breakpoints. Cancer Res 2000; 60(7):1949-60.
10. Wistuba II, Mao L, Gazdar AF. Smoking molecular damage in bronchial epitheliu. Oncogene Oct 21, 2002; 21(48):7298-306.
11. Wistuba II, Lam S, Behrens C et al. Molecular damage in the bronchial epithelium of current and former smokers. J Natl Cancer Inst 1997; 89:1366-73.
12. Mao L, Lee JS, Kurie JM et al. Clonal genetic alterations in the lungs of current and former smokers. J Natl Cancer Inst 1997; 89:857-62.
13. Mulshine JL. Current issues in lung cancer screening. Oncology (Williston Park) Nov 2005; 19(13):1724-30; discussion 30-1.
14. Lam S, MacAulay C, leRiche JC, Palcic B. Detection and localization of early lung cancer by fluorescence bronchoscopy. Cancer Dec 1, 2000; 89(Suppl 11): 2468-73.
15. Westra WH. Early glandular neoplasia of the lung. Respir Med 2000; 1:163-9.
16. Keith RL, Miller YE, Gemmill RM et al. Angiogenic squamous dysplasia in bronchi of individuals at high risk for lung cancer. Clin Cancer Res 2000; 6(5):1616-25.
17. Ohtsuka T, Watanabe K, Kaji M, Naruke T, Suemasu K. A clinicopathological study of resected pulmonary nodules with focal pure ground-glass opacity. Eur J Cardiothorac Surg Jul 2006; 30(1):160-3.
18. Kitamura H, Kameda Y, Ito T, Hayashi H. Atypical adenomatous hyperplasia of the lung. Implications for the pathogenesis of peripheral lung adenocarcinoma [see comments]. Am J Clin Pathol 1999; 111(5):610-22.
19. Osanai M, Igarashi T, Yoshida Y. Unique cellular features in atypical adenomatous hyperplasia of the lung: ultrastructural evidence of its cytodifferentiation. Ultrastruct Pathol 2001; 25:367-73.
20. Nakanishi K. Alveolar epithelial hyperplasia and adenocarcinoma of the lung. Arch Pathol Lab Med 1990; 114(4):363-8.
21. Chapman AD, Kerr KM. The association between atypical adenomatous hyperplasia and primary lung cancer. Br J Cancer 2000; 83:632-6.
22. Koga T, Hashimoto S, Sugio K et al. Lung adenocarcinoma with bronchioloalveolar carcinoma component is frequently associated with foci of high-grade atypical adenomatous hyperplasia. Am J Clin Pathol 2002; 117:464-70.
23. Yokose T, Doi M, Tanno K, Yamazaki K, Ochiai A. Atypical adenomatous hyperplasia of the lung in autopsy cases. Lung Cancer 2001; 33:155-61.
24. Armas OA, White DA, Erlanson RA, Rosai J. Diffuse idiopathic pulmonary neuroendocrine cell proliferation presenting as interstitial lung disease. Am J Surg Pathol 1995; 19:963-70.
25. Gazdar AF, Shigematsu H, Herz J, Minna JD. Mutations and addiction to EGFR: the Achilles "heal" of lung cancers? Trends Mol Med Oct 2004; 10(10):481-6.
26. Tang X, Shigematsu H, Bekele BN et al. EGFR tyrosine kinase domain mutations are detected in histologically normal respiratory epithelium in lung cancer patient. Cancer Res Sep 1, 2005; 65(17):7568-72.
27. Wistuba II, Behrens C, Virmani AK et al. Allelic losses at chromosome 8p21-23 are early and frequent events in the pathogenesis of lung cancer. Cancer Res 1999; 59(8):1973-9.
28. Yashima K, Milchgrub S, Gollahon LS et al. Telomerase enzyme activity and RNA expression during the multistage pathogenesis of breast carcinoma. Clin Cancer Res 1998; 4(1):229-34.
29. Miyazu YM, Miyazawa T, Hiyama K et al. Telomerase expression in noncancerous bronchial epithelia is a possible marker of early development of lung cance. Cancer Res Nov 1, 2005; 65(21):9623-7.
30. Lantuejoul S, Soria JC, Morat L et al. Telomere shortening and telomerase reverse transcriptase expression in preinvasive bronchial lesion. Clin Cancer Res Mar 1, 2005; 11(5):2074-82.
31. Park IW, Wistuba II, Maitra A et al. Multiple clonal abnormalities in the bronchial epithelium of patients with lung cancer [in process citation]. J Natl Cancer Inst 1999; 91(21):1863-8.
32. Zochbauer-Muller S, Fong KM, Maitra A et al. 5' CpG island methylation of the FHIT gene is correlated with loss of gene expression in lung and breast cancer. Cancer Res 2001; 61(9):3581-5.
33. Zochbauer-Muller S, Lam S, Toyooka S et al. Aberrant methylation of multiple genes in the upper aerodigestive tract epithelium of heavy smoker. Int J Cancer Nov 20, 2003; 107(4):612-6.
34. Soria JC, Rodriguez M, Liu DD, Lee JJ, Hong WK, Mao L. Aberrant promoter methylation of multiple genes in bronchial brush samples from former cigarette smoker. Cancer Res Jan 15, 2002; 62(2):351-5.
35. Belinsky SA, Nikula KJ, PalmisanoWA et al. Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci U S A 1998; 95(20):11891-6.
36. Belinsky SA, Palmisano WA, Gilliland FD et al. Aberrant promoter methylation in bronchial epithelium and sputum from current and former smoker. Cancer Res Apr 15, 2002; 62(8):2370-7.
37. Belinsky SA, Liechty KC, Gentry FD et al. Promoter hypermethylation of multiple genes in sputum precedes lung cancer incidence in a high-risk cohor. Cancer Res Mar 15, 2006; 66(6):3338-44.
38. Toyooka S, Tokumo M, ShigematsuHet al. Mutational and epigenetic evidence for independent pathways for lung adenocarcinomas arising in smokers and never smoker. Cancer Res Feb 1, 2006; 66(3):1371-5.
39. Lerman MI, Minna JD. The 630-kb lung cancer homozygous deletion region on human chromosome 3p21.3: identification and evaluation of the resident candidate tumor suppressor gene. The International Lung Cancer Chromosome 3p21.3 Tumor Suppressor Gene Consortium. Cancer Res 2000; 60(21):6116-33.
40. Zabarovsky ER, Lerman MI, Minna JD. Tumor suppressor genes on chromosome 3p involved in the pathogenesis of lung and other cancer. Oncogene Oct 7, 2002; 21(45):6915-35.
41. Rahman SM, Shyr Y, Yildiz PB et al. Proteomic patterns of preinvasive bronchial lesion. Am J Respir Crit Care Med Dec 15, 2005; 172(12):1556-62.
42. Jorgensen ED, Dozmorov I, Frank MB, Centola M, Albino AP. Global gene expression analysis of human bronchial epithelial cells treated with tobacco condensates. Cell Cycle Sep 2004; 3(9):1154-68.
43. Hirsch FR, Franklin WA, Gazdar AF, Bunn PA, Jr. Early detection of lung cancer: clinical perspectives of recent advances in biology and radiology. Clin Cancer Res Jan 2001; 7(1):5-22.
44. Hirsch FR, Prindiville SA, Miller YE et al. Fluorescence versus white-light bronchoscopy for detection of preneoplastic lesions: a randomized stud. J Natl Cancer Inst Sep 19, 2001; 93(18):1385-91.
45. Merrick DT, Haney J, Petrunich S et al. Overexpression of vascular endothelial growth factor and its receptors in bronchial dysplasia demonstrated by quantitative RT-PCR analysis. Lung Cancer Apr 2005; 48(1):31-45.
46. Santarpia M, Altavilla G, Salazar F, Taron M, Rosell R. From the bench to the bed: individualizing treatment in non-small-cell lung cancer. Clin Transl Oncol Feb 2006; 8(2):71-6.
47. Abbruzzese JL, Lippman SM. The convergence of cancer prevention and therapy in early-phase clinical drug development. Cancer Cell Oct 2004; 6(4):321-6.
48. Hirsch FR, Lippman SM. Advances in the biology of lung cancer chemopreventio. J Clin Oncol May 10, 2005; 23(14):3186-97.
49. Khuri FR, Cohen V. Molecularly targeted approaches to the chemoprevention of lung cancer. Clin Cancer Res Jun 15, 2004; 10(12, Pt 2):4249s-53s.
50. Wislez M, Spencer ML, Izzo JG et al. Inhibition of mammalian target of rapamycin reverses alveolar epithelial neoplasia induced by oncogenic K-ra. Cancer Res Apr 15, 2005; 65(8):3226-35.
51. Wislez M, Fujimoto N, Izzo JG et al. High expression of ligands for chemokine receptor CXCR2 in alveolar epithelial neoplasia induced by oncogenic KRA. Cancer Res Apr 15, 2006; 66(8):4198-207.
52. Merrick DT, Kittelson J,Winterhalder R et al. Analysis of c-ErbB1/epidermal growth factor receptor and c-ErbB2/HER-2 expression in bronchial dysplasia: evaluation of potential targets for chemoprevention of lung cancer. Clin Cancer Res Apr 1, 2006; 12(7, Pt 1):2281-8.
53. Tsao AS, McDonnell T, Lam S et al. Increased phospho-AKT (Ser(473)) expression in bronchial dysplasia: implications for lung cancer prevention studies. Cancer Epidemiol Biomarkers Prev Jul 2003; 12(7):660-4.
54. Lee HY, Oh SH,Woo JK et al. Chemopreventive effects of deguelin, a novel Akt inhibitor, on tobacco-induced lung tumorigenesi. J Natl Cancer Inst Nov 16, 2005; 97(22):1695-9.
55. Lee HY, Moon H, Chun KH et al. Effects of insulin-like growth factor binding protein-3 and farnesyltransferase inhibitor SCH66336 on Akt expression and apoptosis in non-small-cell lung cancer cell. J Natl Cancer Inst Oct 20, 2004; 96(20):1536-48.
56. Westra WH, Baas IO, Hruban RH et al. K-ras oncogene activation in atypical alveolar hyperplasias of the human lung. Cancer Res 1996; 56:2224-8.
57. Tominaga M, Sueoka N, Irie K et al. Detection and discrimination of preneoplastic and early stages of lung adenocarcinoma using hmRNP B1, combined with the cell cycle-related markers p16, cyclin D1, and Ki-67. Lung Cancer 2003; 40:45-53.
58. Nakanishi K, Kawai T, Kumaki F, Hiroi S, Mukai M, Ikeda E. Survivin expression in atypical adenomatous hyperplasia of the lung. Am J Clin Pathol 2003; 120:712-9.
59. Kitaguchi S, Takeshima Y, Nishisaka T, Inai K. Proliferative activity, p53 expressin and loss of heterozygosity on 3p, 9 and 17p in atypical adenomatous hyperplasia of the lung. Hiroshima J Med Sci 1998; 47:17-25.
60. Takamochi K, Ogura T, Suzuki K et al. Loss of heterozygosity on chromosome 9q and 16p in atypical adenomatous hyperplasia concomitant with adenocarcinoma of the lung. Am J Pathol 2001; 159:1941-8.
61. Nakanishi K, Kawai T, Kumaki F, Hirot S, Mukai M, Ikeda E. Expression of human telomerase RNA component and telomerase reverse transcriptase mRNA in atypical adenomatous hyperplasia of the lung. Hum Pathol 2002; 33:697-702.
62. Ghaffar H, Sahin F, Sanchez-Cespedes M et al. LKB1 protein expression in the evolution of glandular neoplasia of the lung. Clin Cancer Res 2003; 9:2998-3003.
63. Nikitin AY, Alcaraz A, Anver MR et al. Classification of proliferative pulmonary lesions of the mouse: recommendations of the mouse models of human cancers consortiu. Cancer Res Apr 1, 2004; 64(7):2307-16.
64. Kim CF, Jackson EL, Woolfenden AE et al. Identification of bronchioalveolar stem cells in normal lung and lung cance. Cell Jun 17, 2005; 121(6):823-35.
65. Collado M, Gil J, Efeyan A et al. Tumour biology: senescence in premalignant tumour. Nature Aug 4, 2005; 436(7051):642.
66. Auerbach O, Stout AP, Hammond EC, Garfinkel L. Changes in bronchial epithelium in relation to smoking and cancer of the lung. N Engl J Med 1961; 265:253-67.
67. Slaughter DP, Southwick HW, SmejkalW. "Field cancerization" in oral stratified squamous epithelium: clinical implications of multicentric origin. Cancer 1954; 6(963):963-8.
68. Coussens LM, Werb Z. Inflammation and cance. Nature Dec 19-26, 2002; 420(6917):860-7.
69. Ballaz S, Mulshine JL. The potential contributions of chronic inflammation to lung carcinogenesis. Clin Lung Cancer Jul 2003; 5(1):46-62.
70. Anderson GP, Bozinovski S. Acquired somatic mutations in the molecular pathogenesis of COPD. Trends Pharmacol Sci Feb 2003; 24(2):71-6.
71. Hogg JC. Pathophysiology of airflow limitation in chronic obstructive pulmonary diseas. Lancet Aug 21-27, 2004; 364(9435):709-21.
72. Barnes PJ. Chronic obstructive pulmonary diseas. N Engl J Med Jul 27, 2000; 343(4):269-80.
73. Hida T, Kozaki K, MuramatsuHet al. Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines. Clin Cancer Res May 2000; 6(5):2006-11.
74. Kennedy TC, Proudfoot SP, Franklin WA et al. Cytopathological analysis of sputum in patients with airflow obstruction and significant smoking histories. Cancer Res 1996; 56(20):4673-8.
75. Lam S, LeRiche JC, Zheng Y et al. Sex-related differences in bronchial epithelial changes associated with tobacco smoking. J Natl Cancer Inst 1999; 91(8):691-6.
76. Tsurutani J, Castillo SS, Brognard J et al. Tobacco components stimulate Akt-dependent proliferation and NFκB-dependent survival in lung cancer cells. Carcinogenesis Jul 2005; 26(7):1182-95.
77. Tang X, Liu D, Shishodia S et al. Nuclear factor-kB (NFkB) is frequently activated in lung cancer and preneoplastic lesion. Cancer Dec 1, 2006; 107(11):2637-46.
78. Tichelaar JW, Zhang Y, LeRiche JC, Biddinger PW, Lam S, Anderson MW. Increased staining for phospho-Akt, p65/RELA and cIAP-2 in pre-neoplastic human bronchial biopsies. BMC Cancer 2005; 5:155.
79. Aggarwal BB. Nuclear factor-kappaB: the enemy within. Cancer Cell Sep 2004; 6(3):203-8.
80. Karin M, Greten FR. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol Oct 2005; 5(10):749-59.
81. Pikarsky E, Porat RM, Stein I et al. NF-kappaB functions as a tumour promoter in inflammation-associated cance. Nature Sep 23, 2004; 431(7007):461-6.
82. Kumar A, Takada Y, Boriek AM, Aggarwal BB. Nuclear factor-kappaB: its role in health and disease. J Mol Med Jul 2004; 82(7):434-48.
83. Shishodia S, Aggarwal BB. Nuclear factor-kappaB: a friend or a foe in cancer? Biochem Pharmacol Sep 15, 2004; 68(6):1071-80.
84. Dannenberg AJ, Altorki NK, Boyle JO et al. Cyclooxygenase 2: a pharmacological target for the prevention of cancer. Lancet Oncol Sep 2001; 2(9):544-51.
85. Hasturk S, Kemp B, Kalapurakal SK, Kurie JM, Hong WK, Lee JS. Expression of cyclooxygenase-1 and cyclooxygenase-2 in bronchial epithelium and nonsmall cell lung carcinom. Cancer Feb 15, 2002; 94(4):1023-31.
86. Mao JT, Cui X, Reckamp K et al. Chemoprevention strategies with cyclooxygenase-2 inhibitors for lung cancer. Clin Lung Cancer Jul 2005; 7(1):30-9.
87. Mascaux C, Martin B, Verdebout JM, Ninane V, Sculier JP. COX-2 expression during early lung squamous cell carcinoma oncogenesis. Eur Respir J Aug 2005; 26(2):198-203.
88. Mao JT, Fishbein MC, Adams B et al. Celecoxib decreases Ki-67 proliferative index in active smoker. Clin Cancer Res Jan 1, 2006; 12(1):314-20.
89. Paez JG, Janne PA, Lee JC et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therap. Science Jun 4, 2004; 304(5676):1497-500.
90. Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitini. N Engl J Med May 20, 2004; 350(21):2129-39.
91. Pao W, Miller V, Zakowski M et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotini. Proc Natl Acad Sci U S A Sep 7, 2004; 101(36):13306-11.
92. Huang SF, Liu HP, Li LH et al. High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwa. Clin Cancer Res Dec 15, 2004; 10(24):8195-203.
93. Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T, Mitsudomi T. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implication. Cancer Res Dec 15, 2004; 64(24):8919-23.
94. Tokumo M, Toyooka S, Kiura K et al. The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancer. Clin Cancer Res Feb 1, 2005; 11(3):1167-73.
95. Shigematsu H, Lin L, Takahashi T et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancer. J Natl Cancer Inst Mar 2, 2005; 97(5):339-46.
96. Shigematsu H, Takahashi T, Nomura M et al. Somatic mutations of the HER2 kinase domain in lung adenocarcinoma. Cancer Res Mar 1, 2005; 65(5):1642-6.
97. Amann J, Kalyankrishna S, Massion PP et al. Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cance. Cancer Res Jan 1, 2005; 65(1):226-35.
98. Cappuzzo F, Hirsch FR, Rossi E et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cance. J Natl Cancer Inst May 4, 2005; 97(9):643-55.
99. Hirsch FR, Varella-Garcia M, McCoy J et al. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Stud. J Clin Oncol Oct 1, 2005; 23(28):6838-45.
100. Tsao MS, Sakurada A, Cutz JC et al. Erlotinib in lung cancer-molecular and clinical predictors of outcom. N Engl J Med Jul 14, 2005; 353(2):133-44.
101. Yatabe Y, Kosaka T, Takahashi T, Mitsudomi T. EGFR mutation is specific for terminal respiratory unit type adenocarcinoma. Am J Surg Pathol May 2005; 29(5):633-9.
102. Yoshida Y, Shibata T, Kokubu A et al. Mutations of the epidermal growth factor receptor gene in atypical adenomatous hyperplasia and bronchioloalveolar carcinoma of the lung. Lung Cancer Oct 2005; 50(1):1-8.